PDCD1 and non-small cell lung carcinoma: In addition, there is early evidence to show that VOC patterns detected by eNose can also predict response to novel cancer treatments, as demonstrated in patients with advanced non-small cell lung cancer and anti-programmed cell death 1 (anti-PD-1) immunotherapy [16].